Addiction to RUNX in lymphoma.
Molecular Oncology Laboratory, Centre for Virus Research, Institute of Infection, Immunity and Inflammation, University of Glasgow, Bearsden Glasgow G61 1QH, UK.
James C
JC
Neil
Molecular Oncology Laboratory, Centre for Virus Research, Institute of Infection, Immunity and Inflammation, University of Glasgow, Bearsden Glasgow G61 1QH, UK.
Gillian
G
Borland
Molecular Oncology Laboratory, Centre for Virus Research, Institute of Infection, Immunity and Inflammation, University of Glasgow, Bearsden Glasgow G61 1QH, UK.
Anna
A
Kilbey
D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D050657:Core Binding Factor alpha Subunits / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D015398:Signal Transduction
D000970:Antineoplastic Agents; D050657:Core Binding Factor alpha Subunits
Myc; RUNX; lymphoma; oncogene addiction; p53
Nat Genet. 2014 Feb;46(2):116-25
24413735
Nat Rev Cancer. 2005 May;5(5):376-87
15864279
Cell Rep. 2013 Sep 26;4(6):1131-43
24055056
Cancer Res. 2006 Feb 15;66(4):2195-201
16489021
Oncotarget. 2016 Apr 26;7(17):22973-87
27056890
Cell Stem Cell. 2015 Aug 6;17(2):165-77
26165925
EBioMedicine. 2016 Jun;8:117-31
27428424